GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection

This study has been completed.

Sponsor:

Hoffmann-La Roche

ClinicalTrials.gov Identifier:

NCT00105079

First Posted: March 7, 2005

Last Update Posted: November 2, 2011

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

Detailed information for Adverse Events and Serious Adverse Events will be represented in the SAE/AE section of PRS.

Time Frame

reported up to 28 days after the last dose of study treatment. (Up to 52 weeks)

Population Description

Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

Safety population included all randomized patients who received at least one dose of study medication